Pfizer wins monopoly lawsuit over drug pricing

The federal court in Connecticut dismissed a broad antitrust lawsuit filed by more than 45 U.S. states against Pfizer, accusing it of manipulating the prices of various generic drugs between 2010 and 2014, including products used to treat high blood pressure, glaucoma, and acne. The judge confirmed that allegations of direct collusion between Pfizer and Greenstone are unsubstantiated, and that Greenstone was operating to generate its own profits. The prosecution did not prove that Pfizer was aware of or responsible for the alleged collusion. Greenstone was separated from Pfizer in 2020 as part of a deal to establish the company Vitras.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل